Our data has emphasized on the promising results of FoxM1 suppression in resistant HCC cells, such as the Hep3B cell line, in re-sensitizing them to anticancer therapeutics, including Artemisinin (Figures 3, 4) and we found enhanced tumor suppressive impact of Artemisinin in presence of the FoxM1 inhibitor, Thiostrepton (Figures 5, 6). Here, FOXM1 is linked to hepatocellular carcinoma.